Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1547-1554

  Hellstrom, W J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TAMSULOSIN; VARDENAFIL;

ABNORMAL VISION; BACKACHE; CLINICAL TRIAL; DATA ANALYSIS; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FLUSHING; HUMAN; INFORMATION PROCESSING; MYALGIA; NAUSEA; NOSE CONGESTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; URINARY TRACT INFECTION;

HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34547766493     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01482.x     Document Type: Review

References (83)

1. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994 151 : 54 61.
2. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995 22 : 699 709.
3. Ansong KS, Lewis C, Jenkins P, Bell J. Epidemiology of erectile dysfunction: a community-based study in rural New York State. Ann Epidemiol 2000 10 : 293 6.
4. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004 171 : 2341 5.
5. Stein RA. Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. Rev Urol 2003 5 (Suppl. 7 S21 7.
6. Roose SP. Depression: links with ischemic heart disease and erectile dysfunction. J Clin Psychiatry 2003 64 (Suppl. 10 26 30.
7. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003 108 : 239 44.
8. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999 84 : 11N 7N.
9. Carson CC 3rd. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005 96 : 37M 41M.
10. Montorsi F, Briganti A, Salonia A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003 44 : 360 4.
11. Greenstein A, Chen J, Miller H et al. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997 9 : 123 6.
12. Dhabuwala CB, Kumar A, Pierce JM. Myocardial infarction and its influence on male sexual function. Arch Sex Behav 1986 15 : 499 504.
13. Taylor HA Jr. Sexual activity and the cardiovascular patient: guidelines. Am J Cardiol 1999 84 : 6N 10N.
14. Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005 294 : 2996 3002.
15. Russell ST, Khandheria BK, Nehra A. Erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2004 79 : 782 94.
16. Burnett AL, Lowenstein CJ, Bredt DS et al. Nitric oxide: a physiologic mediator of penile erection. Science 1992 257 : 401 3.
17. Fukumura D, Gohongi T, Kadambi A et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001 98 : 2604 9.
18. Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 2006 18 : 55 60.
19. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996 93 : 210 4.
20. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 288 : 373 6.
21. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003 92 : 37M 46M.
22. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003 92 : 26M 36M.
23. Katz SD, Balidemaj K, Homma S et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000 36 : 845 51.
24. Desouza C, Parulkar A, Lumpkin D et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002 25 : 1336 9.
25. Halcox JP, Nour KR, Zalos G et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002 40 : 1232 40.
26. Foresta C, Lana A, Cabrelle A et al. PDE-5 inhibitor, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 2005 17 : 377 80.
27. Foresta C, Ferlin A, De Toni L et al. Circulating endothelial progenitor cells and endothelial function after chronic tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006 18 : 484 8.
28. Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res 2006 18 : 464 9.
29. Rosano GM, Aversa A, Vitale C et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005 47 : 214 20.
30. Viagra®. Sildenafil citrate [package insert]. New York, NY : Pfizer, Inc., 2006.
31. Cialis®. Tadalafil [package insert]. Indianapolis, IN : Eli Lilly & Co., 2005.
32. Levitra®. Vardenafil HCl [package insert]. West Haven, CT : Bayer Pharmaceuticals Corporation, 2005.
33. Kostis JB, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005 96 : 313 21.
34. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006 3 : 28 36.
35. Management of erectile dysfunction. American urological association (AUA). Education and research Inc, website (2005). Available at http://www.auanet.org/guidelines/edmgmt.cfm (Accessed 11 June 2007).
36. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001 14 : 70 3.
37. Pickering TG, Shepherd AM, Puddey I et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004 17 : 1135 42.
38. Aranda P, Ruilope LM, Calvo C et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004 17 : 139 45.
39. Goldstein I, Kim E, Steers W et al. High prevalence of significant comorbid conditions in men with erectile dysfunction: momentous trial demonstrates efficacy and safety of tadalafil in this group. J Urol 2005 173 : 238 (Abstract 875).
40. Lewis RW, Sadovsky R, Eardley I et al. The efficacy of tadalafil in clinical populations. J Sex Med 2005 2 : 517 31.
41. Padma-Nathan H, Porst H, Eardley I, Thibonnier M. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Am J Hypertens 2002 15 (4 Suppl. 1 48A.
42. van Ahlen H, Wahle K, Kupper W et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005 2 : 856 64.
43. van Ahlen H, Faich G, Morganroth J. Cardiovascular safety of the combination of vardenafil and alpha-blockers: a subgroup analysis of the post-marketing surveillance study 'real life safety and efficacy' of vardenafil (REALISE). J Urol 2005 173 : 200 (Abstract 734).
44. Valiquette L, Young JM, Moncada I et al. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005 80 : 1291 7.
45. Valiquette L, Montorsi F, Auerbach S. First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int J Clin Pract 2006 60 : 1378 85.
46. Steers W, Guay AT, Leriche A et al. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res 2001 13 : 261 7.
47. Young JM, Bennett C, Gilhooly P et al. Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. Urology 2002 60 (2 Suppl. 2 39 48.
48. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005 2 : 415 25.
49. Hellstrom WJ, Gittelman M, Karlin G et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003 61 (4 Suppl. 1 8 14.
50. Valiquette L, Auerbach S, Nathan HP et al. Vardenafil provides initial and subsequent penetration reliability in patients with a high rate of comorbidities and erectile dysfunction: the reliability-vardenafil for erectile dysfunction II (RELY-II) trial. J Sex Med 2006 3 (Suppl. 1 62 63 (Abstract 154).
51. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999 281 : 421 6.
52. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001 44 : 1296 301.
53. Stuckey BG, Jadzinsky MN, Murphy LJ et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003 26 : 279 84.
54. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002 25 : 2159 64.
55. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004 47 : 1914 23.
56. Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 26 : 777 83.
57. Ziegler D, Merfort F, Van Ahlen H et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in type 1 diabetic patients with erectile dysfunction. Diabetes 2005 54 : A127 (Abstract 514-P).
58. Fischer J, Young J, Yale J-F et al. Vardenafil increases the percent of patients achieving initial SEP2/SEP3 success by the 3rd attempt in diabetic men with erectile dysfunction. Diabetes 2004 53 (Suppl. 2 A26 (Abstract 110).
59. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003 57 : 597 600.
60. Shakir SA, Wilton LV, Boshier A et al. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001 322 : 651 2.
61. Jackson G, Kloner RA, Costigan TM et al. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004 1 : 161 7.
62. Kloner RA, Mohan P, Norenberg C et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE5 inhibitor in patients with erectile dysfunction: An analysis of five placebo-controlled clinical trials. Pharmacotherapy 2002 22 : 1371.
63. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 2005 96 : 443 6.
64. Hellstrom WJG, White WB, Sprenger K et al. Cardiovascular safety of vardenafil in patients on antihypertensive therapies and alpha-blockers: finding from analyses of 17 placebo-controlled clinical trials. J Urol 2005 173 : 200 (Abstract 873).
65. Auerbach SM, Gittelman M, Mazzu A et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004 64 : 998 1003.
66. Kloner RA, Jackson G, Emmick JT et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004 172 : 1935 40.
67. Giuliano F, Kaplan SA, Cabanis MJ et al. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006 67 : 1199 204.
68. Zusman RM, Morales A, Glasser DB et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999 83 : 35C 44C.
69. Gori T, Sicuro S, Dragoni S et al. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005 111 : 742 6.
70. Borer J, Armstrong P. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation 2003 107 : e9052.
71. Morganroth J, Ilson BE, Shaddinger BC et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004 93 : 1378 83 (A6).
72. Tomsak R. PDE5 inhibitors and permanent visual loss. Int J Impot Res 2005 17 : 547 9.
73. US Food and Drug Administration. FDA Alert for Healthcare Professionals [Vardenafil]. http://www.fda.gov/cder/drug/InfoSheets/HCP/vardenafilHCP.pdf (Accessed 11 June 2007).
74. McGwin G Jr., Vaphiades MS, Hall TA, Owsley C. Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 2006 90 : 154 7.
75. Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006 60 : 500 3.
76. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate for erectile dysfunction. J Sex Med 2006 3 : 12 27.
77. Alibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging 2004 35 : 165 7.
78. Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 1999 44 : 153 62.
79. Quiram P, Dumars S, Parwar B, Sarraf D. Viagra-associated serous macular detachment. Graefes Arch Clin Exp Ophthalmol 2005 243 : 339 44.
80. Abramson DH, Rollins IS, Lin A et al. Tadalafil-associated subretinal and choroidal hemorrhage in a patient with an unsuspected uveal (choroidal and ciliary body) melanoma. Arch Ophthalmol 2006 124 : 1058 60.
81. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005 80 : 1270 7.
82. Sheu JY, Chen KK, Lin AT et al. Long-term efficacy and safety of sildenafil for patients with erectile dysfunction. J Chin Med Assoc 2003 66 : 480 6.
83. Stief C, Porst H, Saenz De Tejada I et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004 58 : 230 9.